Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy

Mataichi Sekiya; Munehide Nakatsugawa; Nobuyuki Koyama; Naohiro Kajiwara; Takuya Aoki

doi:10.12659/AJCR.951075

27 January 2026 : Case report Japan

Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy

Unusual clinical course, Unusual or unexpected effect of treatment

Mataichi Sekiya^{ABDEF 1*}, Munehide Nakatsugawa^{BCD 2}, Nobuyuki Koyama

^{ABD 1}, Naohiro Kajiwara^{ABD 3}, Takuya Aoki^{ABDEF 1}

DOI: 10.12659/AJCR.951075

Am J Case Rep 2026; 27:e951075

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 5 Immunohistochemical staining of the tumor. The tumor-infiltrating lymphocytes (TILs) were analyzed by immunohistochemical detection using (A) anti-CD3, (B) anti-CD20, (C) anti-CD8, and (D) anti-CD4. Scale bar, 50 μm. Most TILs were CD3+ T cells. The extents of infiltration by CD4+ and CD8+ T cells were similar. Very little CD20+ B cell infiltration was observed.

Back to the Article

Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy

Your Privacy